false
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
Novel combinations for treatment of recurrent cerv ...
Recording
Recording
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this video, Dr. Brad Monk discusses the advances in the treatment of recurrent cervical carcinoma. He highlights the development of drugs for gynecologic malignancies and focuses on the advances in cervical cancer treatment, particularly for recurrent metastatic cancer. Dr. Monk discusses the landmark discoveries in chemotherapy and radiation, GOG204 platinum taxane, and the addition of bevacizumab to chemotherapy. He also talks about the approval and effectiveness of pembrolizumab in the treatment of cervical cancer. Dr. Monk mentions the recent approval of teseotamab vedotin, an antibody drug conjugate, for the treatment of cervical cancer. He explains the safety and efficacy data of TV-carbo and TV-pembro combinations in first-line and second-line treatments. Dr. Monk also touches on the importance of testing for HER2 expression in cervical cancer and discusses the potential future combinations and trials in cervical cancer treatment. The summary is based on the transcript of the video provided.
Keywords
cervical cancer treatment
recurrent metastatic cancer
chemotherapy and radiation
bevacizumab
pembrolizumab
teseotamab vedotin
HER2 expression
Contact
education@igcs.org
for assistance.
×